[go: up one dir, main page]

CO6300795A2 - AN ADENOVIRIC VECTOR OF SIMIO FOR USE IN A VACCINE - Google Patents

AN ADENOVIRIC VECTOR OF SIMIO FOR USE IN A VACCINE

Info

Publication number
CO6300795A2
CO6300795A2 CO10070274A CO10070274A CO6300795A2 CO 6300795 A2 CO6300795 A2 CO 6300795A2 CO 10070274 A CO10070274 A CO 10070274A CO 10070274 A CO10070274 A CO 10070274A CO 6300795 A2 CO6300795 A2 CO 6300795A2
Authority
CO
Colombia
Prior art keywords
viral vector
vector
adenoviric
simio
vaccine
Prior art date
Application number
CO10070274A
Other languages
Spanish (es)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300795(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO6300795A2 publication Critical patent/CO6300795A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un vector adenovírico de simio deficiente de replicación C7 que codifica una proteína que comprende la proteína CS de P. falciparum o un fragmento de la misma, por ejemplo como se muestra en la SEC ID N° 1 o la SEC ID N° 3. La invención se refiere también a procedimientos de preparación de dicho vector vírico y al uso del vector vírico en el tratamiento/prevención de infección por malaria. Se describen también composiciones, vacunas y kits que comprenden dicho vector vírico. En un aspecto, la invención emplea un vector vírico C7 sintético. El vector vírico C7 según la invención puede coadministrarse o coformularse con un antígeno de la malaria tal como RTS,S, opcionalmente en presencia de un coadyuvante, por ejemplo, que comprende 3D-MPL y/o una saponina tal como QS21.The invention relates to a C7 replication deficient ape adenoviral vector encoding a protein comprising P. falciparum CS protein or a fragment thereof, for example as shown in SEQ ID No. 1 or SEQ ID. No. 3. The invention also relates to methods of preparing said viral vector and the use of the viral vector in the treatment / prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect, the invention employs a synthetic C7 viral vector. The viral vector C7 according to the invention can be co-administered or co-formulated with a malaria antigen such as RTS, S, optionally in the presence of an adjuvant, for example, comprising 3D-MPL and / or a saponin such as QS21.

CO10070274A 2007-12-06 2010-06-10 AN ADENOVIRIC VECTOR OF SIMIO FOR USE IN A VACCINE CO6300795A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
CO6300795A2 true CO6300795A2 (en) 2011-07-21

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10070274A CO6300795A2 (en) 2007-12-06 2010-06-10 AN ADENOVIRIC VECTOR OF SIMIO FOR USE IN A VACCINE

Country Status (20)

Country Link
EP (1) EP2227550A2 (en)
JP (1) JP2011505796A (en)
KR (1) KR20100108544A (en)
CN (1) CN101939438A (en)
AR (1) AR069568A1 (en)
AU (1) AU2008333208A1 (en)
BR (1) BRPI0819889A2 (en)
CA (1) CA2707245A1 (en)
CL (1) CL2008003614A1 (en)
CO (1) CO6300795A2 (en)
CR (1) CR11537A (en)
DO (1) DOP2010000164A (en)
IL (1) IL205953A0 (en)
MA (1) MA32003B1 (en)
MX (1) MX2010006207A (en)
PE (1) PE20091106A1 (en)
TW (1) TW200938633A (en)
UY (1) UY31510A1 (en)
WO (1) WO2009071613A2 (en)
ZA (1) ZA201003851B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
MX350795B (en) * 2011-04-08 2017-09-19 Inmune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses.
CN110687289B (en) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Application of FGL2 protein as malaria infection marker

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
CA2502268A1 (en) * 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
CA2880060C (en) * 2004-01-23 2018-03-13 Agostino Cirillo Chimpanzee adenovirus vaccine carriers
BRPI0518146A (en) * 2004-10-14 2008-10-28 Crucell Holland Bv parts kit, use of a recombinant defective adenovirus in replication, and method of vaccinating a mammal for malaria infection
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2008009652A2 (en) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
CN101675068A (en) * 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 Novel methods and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
BRPI0819889A2 (en) 2015-06-16
PE20091106A1 (en) 2009-08-24
TW200938633A (en) 2009-09-16
MX2010006207A (en) 2010-10-04
IL205953A0 (en) 2010-11-30
CA2707245A1 (en) 2009-06-11
WO2009071613A3 (en) 2009-08-13
KR20100108544A (en) 2010-10-07
CR11537A (en) 2010-08-18
JP2011505796A (en) 2011-03-03
MA32003B1 (en) 2011-01-03
EP2227550A2 (en) 2010-09-15
AR069568A1 (en) 2010-02-03
CN101939438A (en) 2011-01-05
AU2008333208A1 (en) 2009-06-11
WO2009071613A2 (en) 2009-06-11
UY31510A1 (en) 2009-08-03
CL2008003614A1 (en) 2010-01-15
DOP2010000164A (en) 2010-07-31
ZA201003851B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
CY1119284T1 (en) PARTICULAR SUBJECTS WITH VIRUS-PROTEIN SOLUTIONS (VLPs)
CY1117673T1 (en) Recombinant RSV antigens
EP4233898A3 (en) Influenza mrna vaccines
AR093712A1 (en) IMMUNOGEN COMPOSITION, VACCINE, USE AND PROCEDURE FOR PREVENTION OR TREATMENT
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2010115133A3 (en) Newcastle disease virus vectored avian vaccines
NZ757882A (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
MX2017014532A (en) VACCINES FOR THE TREATMENT AND PREVENTION OF CANCER.
MX2011011505A (en) Pneumococcal vaccine and uses thereof.
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX344015B (en) VACCINES AND DIAGNOSIS FOR TORQUE TENO VIRUS PORCINO.
AR061894A1 (en) VACCINES FOR MALARIA
BRPI1007721B1 (en) vaccine composition for use in inducing an immune response against a rotavirus in an individual, a rotavirus strain isolated from cdc-9 and a rotavirus strain isolated from cdc-66
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
JP2014521605A5 (en)
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2017003117A (en) Flavivirus virus like particle.
MX2016001695A (en) Combination immunogenic compositions.
CO6300795A2 (en) AN ADENOVIRIC VECTOR OF SIMIO FOR USE IN A VACCINE
ZA202104747B (en) Novel trypanosomal vaccine
NI201700080A (en) VACCINE COMPOSITIONS FOR DENGUE VIRUS AND METHODS OF USE OF THE SAME.
MX2019007924A (en) Influenza vaccines.
UA102274C2 (en) Epitope peptid rab6kifl/kif20a and vaccines containing it

Legal Events

Date Code Title Description
FC Application refused